Dr. Goyal, has 24+ years of senior management and leadership experience at several public and private biotechnology companies where he has raised more than $200 million from public/private investors/federal sources, completed more than $1billion in pharma deals and accomplished several exits. He is currently Chairman and CEO of IMMvention Therapeutix, a company developing novel disease modifying therapies based on pan-inflammasome inhibition for rare and prevalent auto-inflammatory diseases. Prior to IMMvention, at Ribometrix he raised first venture funding round. His experience includes, leading company formation, fund raising, business development, M&A, strategic planning, and senior management roles at Heat Biologics (HTBX), Serenex (led acquisition/sale to Pfizer), Optherion (led acquisition/sale to Sequenom and Baxter), Qualiber, Ascletis (public company on Hong Kong market) and Millennium Pharmaceuticals (acquired by Takeda). In addition to his senior management roles at companies, he has founded OpenDoors Group, a consulting practice to serve as advisor and board member to biotech companies on help execute fund raising, business development, M&A, growth and exit strategies. Dr. Goyal received his Ph.D. degree in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey.
Zefeng Wang, PhD
Dr. Wang, co-founder of Enzerna, received his Ph.D. degree from Johns Hopkins Medical School serves 9 months per year as Director CAS-MPG Partner Institute for Computational Biology (Shanghai CHINA) and 3 months per year as a fractional CSO for Enzerna. Dr. Wang has made significant contribution to the field of RNA biology by developing a series of new methods to study RNA metabolism, including splicing and degradation, and his work has been recognized by several research awards. As an Associate Professor at UNC-Chapel Hill, Dr. Wang developed his patented technology for “Artificial Site-Specific RNA Endonucleases (ASREs)” forms the basis of Enzerna’s core technology.
Joseph Ruiz, PhD
Dr. Ruiz has 14+ years of Director and Executive level leadership experience at four biotechnology startup ventures where he has built research teams to develop genetically engineered stem cell and animal models for drug discovery and therapeutic applications. In particular, as Vice President of Research at Transposagen Biopharmaceuticals, Dr. Ruiz had a pivotal role in developing Transposagen’s Footprint Free Gene Editing technology, which led to the successful launch of Transposgen’s Custom Animal and Cell Engineering Production services In addition to his senior management roles, he founded Emerging Biotechnology Development Services, a consulting practice that guides entrepreneurs’ efforts to establish research operations and secure grant funding for their emerging startup ventures. His efforts has helped over 50 startup ventures throughout the country to secure non-dilutive funds for their research operations. Dr. Ruiz serves on advisory boards and technology review panels at UNC-Chapel Hill as well as a resource for the North Carolina biotech startup community by serving as a panelist in workshops sponsored by the North Carolina Biotechnology Center and the Small Business Technology and Development Center. In addition, Dr. Ruiz has served as a reviewer and frequent chair for NIH Small Business Scientific Review Groups for over 12 years. Dr. Ruiz’s background in both academia and the biotech industry has given him a unique perspective on the importance of developing comprehensive research plans while also driving research toward clinical or commercial applications.